Apolipoprotein E4 in Alzheimer’s Disease

Author(s):

Richard Isaacson, MD,Sharon Cohen, MD, FRCPC

Sharon Cohen, MD, and Marwan Sabbagh, MD, differentiate between the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD), and highlight known risk factors, including the contribution of ApoE gene polymorphism and copy numbers.

Now Viewing

EP: 1.Apolipoprotein E4 in Alzheimer’s Disease

EP: 2.Importance of Early Diagnosis of Alzheimer’s Disease

EP: 3.Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease

EP: 4.Amyloid Cascade Hypothesis of Alzheimer’s Disease

EP: 5.Contribution of Multiple Pathways to the Development of Alzheimer’s Disease

EP: 6.Utilization of Neuroimaging in Alzheimer’s Disease

EP: 7.CSF Testing and Blood-based Biomarkers in Alzheimer’s Disease

EP: 8.Utilization of APOE4 Genotype in Management of Alzheimer’s Disease

EP: 9.Alzheimer’s Disease Pipeline

EP: 10.The Future Outlook for Alzheimer’s Disease

Video content above is prompted by the following question(s):

How are different stages of Alzheimer’s disease (AD; preclinical AD, prodromal AD, and AD with dementia) defined?
1. What are known risk factors for Alzheimer's disease?
  1. Contribution of ApoE gene polymorphism and copy numbers
2. When do patients with Alzheimer’s typically present to the clinic?

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!